Drug intelligence / Profile preview

VS-507

Development stage: Discontinued
Lead developer: Verastem Oncology

Overview

VS-507 is an early-stage investigational small-molecule cancer therapeutic candidate that was being developed by Verastem as part of its oncology pipeline but was not advanced into clinical trials. Available public information indicates that VS-507 was deprioritized based on internal research and strategic considerations, and detailed data on its molecular target, mechanism of action, and specific oncology indications have not been disclosed, suggesting that the program remains at or before preclinical status without active development.

Beyond the preview

Go deeper on VS-507.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VS-507.

Explore the full profile